Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases
Mohammad Afaque Alam*, Ph.D
Department of Pediatrics, College of Medicine, Drexel University, Philadelphia, PA, USA.
- *Corresponding Author:
- Mohammad Afaque Alam
Department of Pediatrics
College of Medicine
Drexel University, 894 Union Ave
Memphis,, TN 38103, USA
E-mail: [email protected]
Received Date: May 09, 2016; Accepted Date: May 13, 2016 ; Published Date: May 21, 2016
Citation: Alam MA (2016) Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases. Cell Dev Biol 5:172. doi:10.4172/2168-9296.1000172
Copyright: © 2016 Alam MA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A growing body of evidence suggests that mutations in MTHFR gene are involved in cardiovascular diseases (CVD) - cardiac development, atherosclerosis, myocardial infarction, heart failure, hypertension, aneurysms- and several other disease- cancers, neurological and metabolic disorders. Genetic variations in other genes are added risk for CVD- a leading cause of morbidity and mortality around the globe. Accumulating data over the decade has enhanced our understanding of MTHFR deficiency and diseases associated risk. The frequency of MTHFR 677 C→T and 1298 A→C gene mutations varies substantially in different regions of the world among different racial and ethnic groups. In particular, 677C→T and 1298 A→C variant are associated with clinical manifestation of almost all noncommunicable diseases. This review describes the roles of MTHFR gene mutation in CVD and prospective therapies for heart disease treatment.